Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study

Abstract Background Cancer survivors are frequently excluded from clinical research, resulting in their omission from the development of many cancer treatment strategies. Quantifying the prevalence of prior cancer in newly diagnosed cancer patients can inform research and clinical practice. This study aimed to describe the prevalence, characteristics, and trends of prior cancer in newly diagnosed cancer patients in Japan. Methods Using Osaka Cancer Registry data, we examined the prevalence, characteristics, and temporal trends of prior cancer in patients who received new diagnoses of lung, stomach, colorectal, female breast, cervical, and corpus uterine cancer between 2004 and 2015. Site-specific prior cancers were examined for a maximum of 15 years before the new cancer was diagnosed. Temporal trends were evaluated using the Cochran-Armitage trend test. Results Among 275,720 newly diagnosed cancer patients, 21,784 (7.9%) had prior cancer. The prevalence of prior cancer ranged from 3.3% (breast cancer) to 11.1% (lung cancer). In both sexes, the age-adjusted prevalence of prior cancer had increased in recent years (P values for trend < 0.001), especially in newly diagnosed lung cancer patients. The proportion of smoking-related prior cancers exceeded 50% in patients with newly diagnosed lung, stomach, colorectal, breast, and cervical cancer. Conclusions The prevalence of prior cancer in newly diagnosed cancer patients is relatively high, and has increased in recent years. Our findings suggest that a deeper understanding of the prevalence and characteristics of prior cancer in cancer patients is needed to promote more inclusive clinical research and support the expansion of treatment options.

Download Full-text

Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: A population-based study

10.21203/rs.3.rs-41046/v2 ◽

2021 ◽

Author(s):

Akira Sato ◽

Keisuke Matsubayashi ◽

Toshitaka Morishima ◽

Kayo Nakata ◽

Koji Kawakami ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Research ◽

Cancer Patients ◽

Uterine Cancer ◽

Treatment Options ◽

Temporal Trends ◽

Treatment Strategies ◽

Population Based ◽

Trend Test ◽

Newly Diagnosed

Abstract Background: Cancer survivors are frequently excluded from clinical research, resulting in their omission from the development of many cancer treatment strategies. Quantifying the prevalence of prior cancer in newly diagnosed cancer patients can inform research and clinical practice. This study aimed to describe the prevalence, characteristics, and trends of prior cancer in newly diagnosed cancer patients in Japan. Methods: Using Osaka Cancer Registry data, we examined the prevalence, characteristics, and temporal trends of prior cancer in patients who received new diagnoses of lung, stomach, colorectal, female breast, cervical, and corpus uterine cancer between 2004 and 2015. Site-specific prior cancers were examined for a maximum of 15 years before the new cancer was diagnosed. Temporal trends were evaluated using the Cochran-Armitage trend test. Results: Among 275,720 newly diagnosed cancer patients, 21,784 (7.9%) had prior cancer. The prevalence of prior cancer ranged from 3.3% (breast cancer) to 11.1% (lung cancer). In both sexes, the age-adjusted prevalence of prior cancer had increased in recent years (P values for trend < 0.001), especially in newly diagnosed lung cancer patients. The proportion of smoking-related prior cancers exceeded 50% in patients with newly diagnosed lung, stomach, colorectal, breast, and cervical cancer. Conclusions: The prevalence of prior cancer in newly diagnosed cancer patients is relatively high, and has increased in recent years. Our findings suggest that a deeper understanding of the prevalence and characteristics of prior cancer in cancer patients is needed to promote more inclusive clinical research and support the expansion of treatment options.

Download Full-text

Increasing Trends in the Prevalence of Prior Cancer in Newly Diagnosed Lung, Stomach, Colorectal, Breast, and Uterine Cancer Patients: A Population-Based Study

10.21203/rs.3.rs-41046/v1 ◽

2020 ◽

Author(s):

Akira Sato ◽

Keisuke Matsubayashi ◽

Toshitaka Morishima ◽

Kayo Nakata ◽

Koji Kawakami ◽

...

Keyword(s):

Breast Cancer ◽

Lung Cancer ◽

Clinical Research ◽

Cancer Patients ◽

Time Trends ◽

Uterine Cancer ◽

Treatment Options ◽

Treatment Strategies ◽

Trend Test ◽

Newly Diagnosed

Abstract Background: Cancer survivors are frequently excluded from clinical research, resulting in their omission from the development of many cancer treatment strategies. Quantifying the prevalence of prior cancer in newly diagnosed cancer patients can inform research and clinical practice. This study aimed to describe the prevalence, characteristics, and trends of prior cancer in newly diagnosed cancer patients in Japan.Methods: Using Osaka Cancer Registry data, we examined the prevalence, characteristics, and time trends of prior cancer in patients who received new diagnoses of lung, stomach, colorectal, female breast, or uterine cancer between 2004 and 2015. Site-specific prior cancers were examined for a maximum of 15 years before the new cancer was diagnosed. Time trends were evaluated using the Cochran-Armitage trend test.Results: Among 275,895 newly diagnosed cancer patients, 21,757 (7.9%) had prior cancer. The prevalence of prior cancer ranged from 3.3% (breast cancer) to 11.1% (lung cancer). In both sexes, the age-adjusted prevalence of prior cancer had increased in recent years (P values for trend < 0.001), especially in newly diagnosed lung cancer patients. The proportion of smoking-related prior cancers exceeded 50% in patients with newly diagnosed lung, stomach, colorectal, and breast cancer.Conclusions: The prevalence of prior cancer in newly diagnosed cancer patients is relatively high, and has increased in recent years. Our findings suggest that a deeper understanding of the prevalence and characteristics of prior cancer in cancer patients is needed to promote more inclusive clinical research and support the expansion of treatment options.

Download Full-text

Using Naïve Bayes Algorithm to Estimate the Response to Drug in Lung Cancer Patients

Combinatorial Chemistry & High Throughput Screening ◽

10.2174/1386207322666190125151624 ◽

2019 ◽

Vol 21 (10) ◽

pp. 734-748 ◽

Cited By ~ 2

Author(s):

Baoling Guo ◽

Qiuxiang Zheng

Keyword(s):

Lung Cancer ◽

Side Effects ◽

Cancer Patients ◽

Drug Response ◽

Treatment Options ◽

Clinical Manifestations ◽

Treatment Strategies ◽

Cancer Resistance ◽

Lung Cancer Patients ◽

Bayes Algorithm

Aim and Objective: Lung cancer is a highly heterogeneous cancer, due to the significant differences in molecular levels, resulting in different clinical manifestations of lung cancer patients there is a big difference. Including disease characterization, drug response, the risk of recurrence, survival, etc. Method: Clinical patients with lung cancer do not have yet particularly effective treatment options, while patients with lung cancer resistance not only delayed the treatment cycle but also caused strong side effects. Therefore, if we can sum up the abnormalities of functional level from the molecular level, we can scientifically and effectively evaluate the patients' sensitivity to treatment and make the personalized treatment strategies to avoid the side effects caused by over-treatment and improve the prognosis. Result & Conclusion: According to the different sensitivities of lung cancer patients to drug response, this study screened out genes that were significantly associated with drug resistance. The bayes model was used to assess patient resistance.

Download Full-text

Racial disparities in bone metastasis patterns and targeted screening and treatment strategies in newly diagnosed lung cancer patients

Ethnicity and Health ◽

10.1080/13557858.2020.1734775 ◽

2020 ◽

pp. 1-14

Author(s):

Guijun Xu ◽

Ping Cui ◽

Chao Zhang ◽

Feng Lin ◽

Yao Xu ◽

...

Keyword(s):

Lung Cancer ◽

Bone Metastasis ◽

Racial Disparities ◽

Cancer Patients ◽

Treatment Strategies ◽

Newly Diagnosed ◽

Lung Cancer Patients ◽

Targeted Screening ◽

Metastasis Patterns

Download Full-text

Lung cancer survival in Norway, 1997–2011: from nihilism to optimism

European Respiratory Journal ◽

10.1183/13993003.00650-2015 ◽

2015 ◽

Vol 47 (1) ◽

pp. 275-287 ◽

Cited By ~ 13

Author(s):

Yngvar Nilssen ◽

Trond Eirik Strand ◽

Lars Fjellbirkeland ◽

Kristian Bartnes ◽

Bjørn Møller

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Cancer Survival ◽

Treatment Options ◽

Diagnostic Testing ◽

Relative Survival ◽

Population Based ◽

Related Factors ◽

Lung Cancer Patients ◽

Lung Cancer Survival

We examine changes in survival and patient-, tumour- and treatment-related factors among resected and nonresected lung cancer patients, and identify subgroups with the largest and smallest survival improvements.National population-based data from the Cancer Registry of Norway, Statistics Norway and the Norwegian Patient Register were linked for lung cancer patients diagnosed during 1997–2011. The 1- and 5-year relative survival were estimated, and Cox proportional hazard regression, adjusted for selected patient characteristics, was used to assess prognostic factors for survival in lung cancer patients overall and stratified by resection status.We identified 34 157 patients with lung cancer. The proportion of histological diagnoses accompanied by molecular genetics testing increased from 0% to 26%, while those accompanied by immunohistochemistry increased from 8% to 26%. The 1-year relative survival among nonresected and resected patients increased from 21.7% to 34.2% and 75.4% to 91.5%, respectively. The improved survival remained significant after adjustment for age, sex, stage and histology. The largest improvements in survival occurred among resected and adenocarcinoma patients, while patients ≥80 years experienced the smallest increase.Lung cancer survival has increased considerably in Norway. The explanation is probably multifactorial, including improved attitude towards diagnostic work-up and treatment, and more accurate diagnostic testing that allows for improved selection for resection and improved treatment options.

Download Full-text

Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study

Journal of Clinical Oncology ◽

10.1200/jco.2007.11.9081 ◽

2008 ◽

Vol 26 (8) ◽

pp. 1239-1246 ◽

Cited By ~ 116

Author(s):

Michael Schaapveld ◽

Otto Visser ◽

Marieke J. Louwman ◽

Elisabeth G.E. de Vries ◽

Pax H.B. Willemse ◽

...

Keyword(s):

Breast Cancer ◽

Lung Cancer ◽

Cancer Patients ◽

Cumulative Incidence ◽

Uterine Cancer ◽

Population Based ◽

Excess Risk ◽

Breast Cancer Patients ◽

Female Population ◽

Cox Regression Analysis

Purpose To assess the risk of secondary nonbreast cancers (SNBCs) in a recently treated population-based cohort of breast cancer patients focused on the association with treatment and prognostic implications. Patients and Methods In 58,068 Dutch patients diagnosed with invasive breast cancer between 1989 and 2003, SNBC risk was quantified using standardized incidence ratios (SIRs), cumulative incidence, and Cox regression analysis, adjusted for competing risks. Results After a median follow-up of 5.4 years, 2,578 SNBCs had occurred. Compared with the Dutch female population at large, in this cohort, the SIR of SNBCs was increased (SIR, 1.22; 95% CI, 1.17 to 1.27). The absolute excess risk was 13.6 (95% CI, 9.7 to 17.6) per 10,000 person-years. SIRs were elevated for cancers of the esophagus, stomach, colon, rectum, lung, uterus, ovary, kidney, and bladder cancers, and for soft tissue sarcomas (STS), melanoma, non-Hodgkin's lymphoma, and acute myeloid leukemia (AML). The 10-year cumulative incidence of SNBCs was 5.4% (95% CI, 5.1% to 5.7%). Among patients younger than 50 years, radiotherapy was associated with an increased lung cancer risk (hazard ratio [HR] = 2.31; 95% CI, 1.15 to 4.60) and chemotherapy with decreased risk for all SNBCs (HR = 0.78; 95% CI, 0.63 to 0.98) and for colon and lung cancer. Among patients age 50 years and older, radiotherapy was associated with raised STS risk (HR = 3.43; 95% CI, 1.46 to 8.04); chemotherapy with increased risks of melanoma, uterine cancer, and AML; and hormonal therapy with all SNBCs combined (HR = 1.10; 95% CI, 1.01 to 1.21) and uterine cancer (HR = 1.78; 95% CI, 1.40 to 2.27). An SNBC worsened survival (HR = 3.98; 95%CI 3.77 to 4.20). Conclusion Breast cancer patients diagnosed in the 1990s experienced a small but significant excess risk of developing an SNBC.

Download Full-text